Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Last updated: December 25, 2024
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Overall Status: Active - Recruiting

Phase

2

Condition

Lymphoma

Non-hodgkin's Lymphoma

Treatment

Azacitidine

prednisone

Chidamide

Clinical Study ID

NCT05958719
IIT2023003
  • Ages > 18
  • All Genders

Study Summary

This study is investigating the effectiveness (specifically the objective response rate - ORR) of a new combination therapy called CAMP (chidamide, azacitidine, liposomal mitoxantrone, and prednisone) for previously untreated angioimmunoblastic T-cell lymphoma (AITL). It's a single-arm study comparing CAMP's safety and efficacy to standard treatments. Younger patients (≤70) receive the full CAMP regimen, while older patients receive a modified version (CAMP-light). Patients are assessed via PET-CT after 4 cycles. Responders (CR/PR) receive consolidation therapy and then maintenance chidamide for 2 years. Eligible patients achieving CR after 4 cycles can get a transplant, while those with PR need 2 more cycles first. Patients with stable or progressive disease after 4 cycles are withdrawn. Progression at any time leads to study discontinuation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Subjects must have histological confirmation of nodal T-follicular helper (TFH) celllymphoma.

  2. More than 18 years of age.

  3. Proper functioning of the major organs: 1) The absolute value of neutrophils (≥1×10^9/L); 2) platelet count (≥75×10^9/L); 3) Serum total bilirubin ≤ 1.5 timesULN; 4) Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) ≤3 timesULN; 5) Serum creatinine (Cr) ≤2 ULN, or glomerular filtration rate ≥40ml/min;

  4. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.

  5. LVEF value measured by echocardiography ≥50%.

  6. Life expectancy > 3 months.

Exclusion

Exclusion Criteria:

  1. Patients who have previously received chemotherapy, radiotherapy or other antitumortherapy.

  2. Patients with central nervous system involvement by lymphoma.

  3. Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulationdisorders, connective tissue diseases, serious infectious diseases and otherdiseases.

  4. Pregnant or breastfeeding women.

  5. Presence of human immunodeficiency virus (HIV) virus infection.

  6. Previous history of other malignant tumors, unless the disease has been cured for 5years or more. The following cured tumors are excluded:

  7. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin andrelated localized non-melanoma skin cancers;

  8. Carcinoma in situ of the cervix

Study Design

Total Participants: 37
Treatment Group(s): 4
Primary Treatment: Azacitidine
Phase: 2
Study Start date:
March 02, 2023
Estimated Completion Date:
March 02, 2027

Study Description

Main Objective:

The primary objective of this study is to investigate the objective response rate (ORR) of chidamide in combination with azacitidine, liposomal mitoxantrone, and prednisone (CAMP regimen) for the treatment of treatment-naïve angioimmunoblastic T-cell lymphoma (AITL).

Study Design:

This study employs a single-arm design, based on the hypothesis that the safety profile of the chidamide, azacitidine, liposomal mitoxantrone, and prednisone (CAMP regimen) is superior to conventional treatment regimens, and that the efficacy, as measured by ORR, is non-inferior to conventional treatment regimens. Patients meeting the inclusion/exclusion criteria will be treated according to age: patients ≤70 years old will receive the CAMP regimen as first-line therapy, while patients >70 years old will receive a modified CAMP regimen (CAMP-light) as first-line therapy. Interim efficacy will be assessed via PET-CT scan after the 4th cycle of chemotherapy, with PET-CT results interpreted using the Deauville 5-point scale.

Treatment and Follow-up:

Patients achieving a complete response (CR) or partial response (PR) at the interim assessment will continue with 2 cycles of consolidation therapy using the CAMP regimen or CAMP-light regimen. Subsequently, they will enter single-agent chidamide maintenance therapy (≤70 years old: chidamide 30mg orally, twice weekly; >70 years old: chidamide 20mg orally, twice weekly), which will continue for 24 months.

Patients eligible for transplantation who achieve a CR after 4 cycles of induction therapy may proceed to autologous stem cell transplantation (ASCT). Patients achieving a PR will receive 2 additional cycles of consolidation therapy before undergoing ASCT. Patients with a PR at the interim assessment will undergo a repeat PET-CT scan before transplantation to reassess efficacy. Stem cell mobilization for transplant-eligible patients will utilize steady-state mobilization with or without plerixafor.

Patients exhibiting stable disease (SD) or progressive disease (PD) at the interim assessment after 4 cycles will be withdrawn from the study.

Patients experiencing PD at any time during the treatment course will be discontinued from the study upon confirmation of progression.

Connect with a study center

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin 300020
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.